阿奇霉素联合转移因子口服溶液治疗小儿肺炎支原体肺炎临床疗效观.docVIP

阿奇霉素联合转移因子口服溶液治疗小儿肺炎支原体肺炎临床疗效观 　【摘要】 目的：探讨阿奇霉素联合转移因子口服溶液对小儿肺炎支原体肺炎的疗效。方法：肺炎支原体肺炎患儿100例随机分为观察组和对照组各50例，观察组采用阿奇霉素联合转移因子口服溶液治疗，对照组单用阿奇霉素。疗程2周结束后观察疗效，随访2月观察有无复发。结果：观察组发热、咳嗽、肺部体征消失和X线胸片恢复时间和对照组比较差异均有统计学意义（Plt;0.05）；两组间治愈率差异有统计学意义（Plt;0.05）；观察组无复发，对照组3例（6％）复发。结论：阿奇霉素联合转移因子口服溶液治疗小儿肺炎支原体肺炎疗程短，治愈率高，复发率低，提示联合用药具有明显的优越性。 【关键词】 肺炎支原体肺炎；免疫调节剂；联合用药 ［Abstract］ Objective:To investigate the therapeutic efficacy of azithromycin with transfer factor oral solution in treatment of children with mycoplasma pneumoniae pneumonia (MPP). Methods: 100 cases of children with MPP were randomly divided into two groups with 50 cases each: the observation group received the combined therapy of azithromycin with transfer factor oral solution, while the control group received the therapy of azithromycin only, and then comparison was made between the two groups in clinical effects in the end of the course of 2 weeks treatment and followup visits were made after 2month to see whether there was any recrudescence. Results: There was a significant difference between the two groups (Plt;0.05) in the time of the disappearance of fever, cough and pulmonary signs and of Xray recovery, and there was also a statistic difference in curative rate (Plt;0.05). No case relapsed in the observation group while 3 cases (6%) in the control group. Conclusions: The combined therapy of azithromycin with transfer factor oral solution has obvious superiority with shorter courses, higher curative rate and lower relapse rate than single azithromycin in treatment of children with MPP. ［Key words］ Mycoplasma pneumoniae pneumonia; Immunoregulant; Drug combination 近年来，随着肺炎病原学的变迁，肺炎支原体（Mycoplasma pneumoniae，MP）感染率明显增加，肺炎支原体已成为儿童肺炎的重要病原，且有流行趋势［1］。小儿肺炎支原体肺炎（Mycoplasma pneumoniae pneumonia，MPP）常年均可发生，治疗不当易致病情加重，迁延不愈。我科2002年5月～2007年5月采用阿奇霉素联合转移因子口服溶液治疗小儿肺炎支原体肺炎50例并与单用阿奇霉素治疗50例进行对照研究，现报道如下。 1 资料与方法 1.1 一般资料 100例均为本院初诊的住院患儿，符合《诸福棠实用儿科学》关于肺炎支原体肺炎的诊断标准［2］，无其他严重并发症﹑肝脏疾病和肝功异常及大环内酯类药物过敏史，入院前1周未用大环内酯类或喹诺酮类药物。将入选病例按入院顺序随机分为观察组和对照组各5